for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

T2 Biosystems Inc

TTOO.OQ

Latest Trade

2.87USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.52

 - 

7.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.87
Open
--
Volume
--
3M AVG Volume
42.91
Today's High
--
Today's Low
--
52 Week High
7.70
52 Week Low
0.52
Shares Out (MIL)
44.54
Market Cap (MIL)
114.01
Forward P/E
-2.14
Dividend (Yield %)
--

Next Event

T2 Biosystems Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

T2 Biosystems Inc - Co Entered Into An Agreement With Biomedical Advanced Research And Development Authority

T2 Biosystems Reprots Q2 Loss Per Share Of $0.35

T2 Biosystems To Sell Up To $30.0 Mln Of Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About T2 Biosystems Inc

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Industry

Medical Equipment & Supplies

Contact Info

101 Hartwell Ave

+1.781.4571200

http://www.t2biosystems.com/

Executive Leadership

John McDonough

Executive Chairman of the Board, President, Chief Executive Officer

Michael J. Cima

Co-Founder, Independent Director

John M. Sprague

Chief Financial Officer

Alec Barclay

Senior Vice President - Operations

Thomas J. Lowery

Chief Scientific Officer

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.100

2017

-1.940

2018

-1.260

2019(E)

-1.196
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.53
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-185.12
Return on Equity (TTM)
-87.66

Latest News

BRIEF-T2 Biosystems Reports Q1 Loss Per Share Of $0.36

* T2 BIOSYSTEMS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-T2 Biosystems Files For Non Timely 10-K

* T2 BIOSYSTEMS INC FILES FOR NON TIMELY 10-K - SEC FILING Source text - http://bit.ly/2ppkjtC Further company coverage:

BRIEF-T2 Biosystems Q4 Revenue Rose 55 Percent To $1.7 Million

* T2 BIOSYSTEMS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-T2 Biosystems Awarded Up To $2 Million By Carb-X To Support Development Of New Tests On The T2Dx Instrument For Drug-Resistant Bacteria

* T2 BIOSYSTEMS AWARDED UP TO $2 MILLION BY CARB-X TO SUPPORT DEVELOPMENT OF NEW TESTS ON THE T2DX INSTRUMENT FOR DRUG-RESISTANT BACTERIA Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems Says John Sprague Has Been Named CFO

* T2 BIOSYSTEMS INC - JOHN SPRAGUE HAS BEEN NAMED CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems CFO Darlene Deptula-Hicks Resigns

* T2 BIOSYSTEMS- ON JAN 30, DARLENE DEPTULA-HICKS NOTIFIED CO OF HER RESIGNATION FROM POSITION AS CO'S CHIEF FINANCIAL OFFICER EFFECTIVE IMMEDIATELY

BRIEF-T2 Biosystems Says ‍Total Q4 Revenue Is Expected To Exceed Previously Guided Range Of $1.1 Mln To $1.3 Mln​

* T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON T2BACTERIA PANEL

BRIEF-T2 Biosystems, SMC Ltd Amend Certain Supply Agreement

* T2 BIOSYSTEMS-ON DEC. 22, CO,SMC, LTD ENTERED INTO SECOND AMENDMENT TO SUPPLY AGREEMENT, AMENDING CERTAIN SUPPLY AGREEMENT, DATED AS OF OCT. 10, 2014

BRIEF-T2 Biosystems Q3 loss per share $0.45

* T2 biosystems reports third quarter 2017 financial results and provides company update

BRIEF-T2 Biosystems announces pricing of public offering of common stock

* T2 Biosystems announces pricing of public offering of common stock

BRIEF-T2 Biosystems announces proposed public offering of common stock

* T2 Biosystems announces proposed public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems submits 510(K) application to the FDA for review of T2Bacteria Panel

* T2 Biosystems submits 510(K) application to the FDA for review of T2Bacteria Panel Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems to collaborate with CDC to detect emerging superbug Candida Auris​

* T2 Biosystems Inc - announces collaboration with CDC to detect emerging superbug Candida Auris Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems entered into amendment to supply agreement as of Oct 10, 2014

* On August 29, Co & Smc Ltd entered into amendment to supply agreement amending certain supply agreement, dated as of Oct 10, 2014

BRIEF-Tiger Management reports 5.68 pct passive stake in T2 Biosystems

* Tiger Management Llc reports 5.68 percent passive stake in T2 biosystems Inc as of may 25 - sec filing Source text -http://bit.ly/2sx5Zjp Further company coverage:

BRIEF-T2 Biosystems names Darlene Deptula-Hicks as CFO

* T2 Biosystems names Darlene Deptula-Hicks as chief financial officer

BRIEF-T2 Biosystems files for resale of up to 6.06 mln shares by selling stockholder

* T2 biosystems inc - files for resale of up to 6.06 million shares of co's common stock, par value $0.001 per share, by selling stockholder Source text for Eikon: (http://bit.ly/2mmhevq) Further company coverage:

BRIEF-T2 Biosystems qtrly loss per share $0.48

* T2 Biosystems Inc - on March 2, Shawn Lynch notified company of his resignation from his position as company's CFO effective immediately

BRIEF-T2 Biosystems reports third quarter results

* Q3 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems announces collaboration with Allergan

* T2 Biosystems announces collaboration with Allergan to develop the first blood-based diagnostic panel to detect antimicrobial resistance

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up